Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration
Oncogenic RAS mutants are key anti-cancer targets as KRas mutations are very frequent in human cancers. Here, the authors engineer a cytosol-penetrating anti-Ras antibody and demonstrate its ability to block RAS-effector protein interactions inhibiting tumour growth of Ras mutant-driven cancers.
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2017-05-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/ncomms15090 |